Top Markets
Coin of the day
Organogenesis Holdings Inc. Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGO
주식 순위 #17996
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that... Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
주가
$1.69
마지막 동기화: 2026-09-02
시가총액
$216.83M
변동 (1일)
3.38%
변동 (1년)
-66.03%
국가
US
거래 Organogenesis Holdings Inc. (ORGO)

카테고리

B의 시가 총액을 가진 ORGO의 가격
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
ORGO
$1.69
의 시가총액 Organogenesis Holdings Inc.(ORGO)
시가총액: $216.83M
September 2026 기준으로 Organogenesis Holdings Inc.의 시가총액은 $216.83M입니다. 이는 당사 데이터에 따르면 Organogenesis Holdings Inc.이 세계에서 17996th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2017부터 2026까지 Organogenesis Holdings Inc.의 시가총액 기록
ORGO 가장 인기있는 상위 5 가지 stocks과 비교하여
ORGO의 가격 자산 b b의 시장 결과
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$42,155.14 $216.83M
$5.424T +2,501,539.97%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$37,116.02 $216.83M
$4.776T +2,202,500.65%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$31,488.85 $216.83M
$4.052T +1,868,563.68%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$28,685.07 $216.83M
$3.691T +1,702,177.25%
Organogenesis Holdings Inc. Organogenesis Holdings Inc.
$21,327.01 $216.83M
$2.744T +1,265,523.00%